Eyestem Receives CDSCO Approval to Initiate Phase 2 Randomized, Controlled Human Trials of Eyecyte-RPE™

VoM News Desk | January 28, 2026 | 12:59 PM IST | Breaking News, Health Care, India | Follow on Google News

Eyestem Receives CDSCO Approval to Initiate Phase 2 Randomized, Controlled Human Trials of Eyecyte-RPE™

India, 28 January 2026: Eyestem Research Pvt Ltd, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate the clinical trial of its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE™ in India. The randomized, controlled phase 2 clinical trials will evaluate the safety and efficacy of Eyecyte-RPE™ in a larger group of subjects with moderate geographic atrophy (GA) and associated vision loss.

The approval follows the successful completion of Eyestem’s Phase 1 clinical study of Eyecyte-RPE™, being developed for patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The study demonstrated an excellent safety profile with clinically meaningful improvements in visual acuity. In subjects with advanced GA and severe vision loss, patients recorded an average improvement of 14.8 letters at six months in the first eight subjects, with sustained gains of an average 14.6 letters observed at one year in five subjects. Importantly, six different surgeons performed the surgery in the Phase 1 study with excellent safety outcomes which validated Eyestem’s unique approach towards delivery of Eyecyte-RPE™ to the intended site of action.

Commenting on the upcoming Phase 2 trial and potential global market entry of Eyecyte-RPE™, Dr Jogin Desai, Founder and CEO, Eyestem, said, “There is no available therapy that reverses blindness caused by geographic atrophy (GA), affecting an estimated 8 million patients worldwide. Eyestem is among a few companies globally pursuing a scalable cell therapy approach toward a potential cure. CDSCO approval enables us to advance Eyecyte-RPE™ into Phase 2 clinical evaluation, allowing broader, randomized validation of our best-in-class Phase 1 outcomes. With AMD projected to affect 288 million people by 2040, this marks a major milestone in our mission to transform retinal care and patient lives worldwide.”

The advancement to Phase 2 of Eyestem’s lead therapy is supported by capital raised in a recent oversubscribed funding round, which is enabling continued clinical development and preparations for global regulatory filings. 

Eyestem is also preparing to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), enabling the planned initiation of clinical studies in the United States.

For more information, please visit: https://clinicaltrials.gov/study/NCT06394232

About Eyecyte-RPE™

Eyecyte-RPE™, derived from human induced pluripotent stem cells (hiPSCs), is Eyestem’s proprietary retinal cell therapy product with a novel composition, developed and patented by Eyestem Research. The product can help replace the damaged or lost retinal pigment epithelial (RPE) cells and potentially enable tissue regeneration in the diseased retina. This unique formulation is allogeneic, scalable, and can be stored as a frozen vial for long periods of time.

About Geographic Atrophy

Dry AMD is the leading cause of blindness for people over 50. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible loss of central vision, characterised by the death of cells in the macula, the central part of the retina. Approximately 196 million people suffer from dry AMD globally, five million of whom suffer from GA.

TimBuckDo Co-Founder Mythri Kumar Calls for Strong Budget Push for Gig Economy Ahead of Union Budget 2026

About Eyestem Research

Headquartered in Bangalore and Delaware, Eyestem Research is a clinical-stage biotechnology company, which was started by a founding team with several decades of experience in pharmaceutical product development, retinal surgery, and cell biology. It has won significant accolades with the most recent one being named the top innovator in India across all sectors in 2022 by the prestigious The Economic Times newspaper. It is also the recipient of several prestigious grants and awards from the Department of Biotechnology (DBT), Government of India, and has been feted at high-profile government events as one of the most successful and innovative biotechnology companies in the country.

VoM News Desk

VoM News is an online web portal in jammu Kashmir offers regional, National & global news.